FDA committee unanimously recommends approval of Grastek
[at theflyonthewall.com] - FDA committee unanimously recommends approval of Grastek
Merck Statement on FDA Advisory Committee for GRASTEKŪ (Timothy Grass Pollen Allergen Extract), Merck?s Investigational Sublingual Allergy Immunotherapy Tablet
[Business Wire] - Merck , known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S.
A Top 10 Wall Street Transcript Portfolio Manager Interview of 2013 with Finny Kuruvilla, M.D., Ph.D., of the Eventide Gilead Fund: Investing in Health Care Innovation Yields 50+% Annual Returns
[Wall Street Transcript] - 67 WALL STREET, New York - December 12, 2013 - The Wall Street Transcript has just published its Top Ten Portfolio Manager Interviews of 2013 Report. This special feature contains expert industry commentary ...
FDA panel says Merck's allergy drug effective
[Reuters] - A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck & Co was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children. The advisory panel voted 9-0 that available data supported the efficacy of the immunotherapy drug, Grastek, in treating Timothy grass pollen allergy in patients 5 years or older. The committee also voted unanimously in favor of the drug's safety, on the condition that patients taking the drug have easy access to epinephrine - a medicine used to treat serious allergic reaction such as ones that can result from the use of immunotherapies. Grastek is an immunotherapy drug which contains extracts of Timothy grass allergen.
Heska Announces Extension of Tri-Heart TM Plus Heartworm Preventive Agreement with Merck Animal Health
[at noodls] - Release date: 12/12/2013 Supply and License Agreement Amended and Extended through 2023 LOVELAND, CO, December 12, 2013 -- Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), ...